The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease-Reference-Cited by-同舟云学术

The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease

Published:2006-10-05 Issue:1 Volume:21 Page:110-120
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Longo P G,Laurenti L,Gobessi S,Petlickovski A,Pelosi M,Chiusolo P,Sica S,Leone G,Efremov D G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404417.pdf

Reference57 articles.

1. Rai KR, Wasil T, Iqbal U, Driscoll N, Patel D, Janson D et al. Clinical staging and prognostic markers in chronic lymphocytic leukemia. Hematol Oncol Clin N Am 2004; 18: 795–805.

2. Chiorazzi N, Ferrarini M . B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003; 21: 841–894.

3. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.

4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854.

5. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647.

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of NFKB1 and MyD88 expression levels in a sample of non-Hodgkin lymphoma patients before and during chemotherapy;Egyptian Journal of Basic and Applied Sciences;2024-05-11

2. Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death;Cell Death & Disease;2024-03-18

3. Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia;European Journal of Immunology;2023-09-04

4. Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation;Leukemia;2023-04-26

5. Macrophage- and BCR-derived but not TLR-derived signals support the growth of CLL and Richter syndrome murine models in vivo;Blood;2022-12-01